

CASE REPORTS

Successful treatment of drug-resistant cataplexy with the anticholinergic drug tropatepine

Milan Nigam, MD^{1,2,3}; Smaranda Leu-Semenescu, MD³; Isabelle Arnulf MD, PhD^{3,4}

¹Centre for Advanced Research in Sleep Medicine, Sacré-Coeur Hospital, Montreal, Québec, Canada; ²Department of Neurosciences, University of Montreal, Montreal, Québec, Canada; ³National Reference Center for Narcolepsy, Sleep Disorders Unit, University Hospital Pitié-Salpêtrière, Paris, France; ⁴Sorbonne University, Paris, France

Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy, as well as hypocretin deficiency. *Cataplexy* (the loss of voluntary postural muscle tone, often in response to emotional stimuli) is one of the most disabling features and is associated with significant social impairment and risk of injury. Cataplexy is usually alleviated by antidepressants sodium oxybate and pitolisant. In this case report, we describe three patients with severe, drug-resistant cataplexy who experienced a dramatic improvement when treated with tropatepine, an anticholinergic muscarinic antagonist (commonly used to prevent neuroleptic-induced parkinsonism) after the usual treatments had failed. The single side effect was mild mouth dryness. In addition to providing a new therapeutic option for resistant cataplexy, this benefit supports a role of cholinergic muscarinic transmission in rapid eye movement sleep atonia.

Keywords: narcolepsy, cataplexy, anticholinergic

Citation: Nigam M, Leu-Semenescu S, Arnulf I. Successful treatment of drug-resistant cataplexy with the anticholinergic drug tropatepine. *J Clin Sleep Med.* 2021;17(4):849–851.

INTRODUCTION

Narcolepsy type 1 is a neurologic disorder caused by the loss of hypocretin-1 neurons in the lateral hypothalamus. It is characterized by excessive daytime sleepiness, sleep attacks, and cataplexy, as well as other variably present symptoms, including sleep paralysis, hypnagogic hallucinations, disturbed nighttime sleep, rapid eye movement (REM) sleep behavior disorder, and weight gain.¹ Cataplexy corresponds to brief loss of bilateral postural voluntary muscle tone, usually triggered by emotional stimuli. It is conceptualized as the intrusion of REM sleep atonia into wakefulness. Attacks can be either partial (ie, loss of facial tone, dysarthria) or complete (ie, involving the whole body and resulting in falls). Both types of cataplexy are a source of significant social impairment, anxiety, and potential injury. Current treatment options for cataplexy include antidepressants (such as venlafaxine, paroxetine, escitalopram, fluoxetine, and clomipramine), sodium oxybate, and pitolisant.^{1,2} Although these agents are usually efficacious, some patients report persistent cataplexy despite multiple drug trials. This report describes three such patients who experienced dramatic improvement after treatment with tropatepine, an anticholinergic muscarinic antagonist, primarily used in France as a treatment for neuroleptic-induced parkinsonism.³ In addition to its practical therapeutic implication, the successful use of this treatment re-emphasizes the importance of cholinergic mechanisms in the neurobiology of cataplexy.

REPORT OF CASES

Patient 1

A 27-year-old man was diagnosed with narcolepsy type 1 at age 10 years after a typical history of rapid weight gain, followed by

progressive onset of excessive daytime sleepiness and cataplexy. The hypocretin-1 level was undetectable (< 40 mg/ml) in the cerebrospinal fluid. He received intravenous immunoglobulins 5 months after cataplexy onset, which led to a decrease in total and partial cataplexy, which gradually reoccurred several months after the infusion.⁴ Over the subsequent years, the patient was treated with several wake-promoting agents with variable success, including modafinil, sodium oxybate, and methylphenidate. The patient reported frequent, highly disabling partial cataplexy attacks characterized by loss of facial, neck, and arm tone, provoked by laughter and lasting up to 1 minute. The attacks occurred dozens of times per day and were associated with significant social impairment and avoidance behaviors, which had a profoundly negative impact on his quality of life. Previous trials of venlafaxine and sodium oxybate for cataplexy were inefficacious, and the combination of pitolisant 36 mg and clomipramine 25 mg resulted in only a minor decrease in frequency of attacks. Methylphenidate, although effective for somnolence, triggered a severe psychotic episode at age 18 years, which was successfully treated with cessation of methylphenidate and introduction of risperidone, which was tapered over a 2-year period. To prevent neuroleptic-induced parkinsonism, tropatepine (Lepticur, a muscarinic anticholinergic) was introduced and titrated up to 10 mg daily. The dose was subsequently reduced to 5 mg because of dry mouth. Within days of the introduction of tropatepine, the patient reported a dramatic reduction in the severity and frequency of cataplexy, with only minor, nondisabling facial cataplexy occurring once per week. He had since been treated with pitolisant 36 mg and reported remarkable efficacy for daytime sleepiness. After 1 year on tropatepine, the patient

attempted a 1-week tropatepine holiday (but still took pitolisant), which caused the cataplexy to return to its pretreatment severity, which remitted once again on resumption of tropatepine. The patient now has been receiving tropatepine for 7 years and has enjoyed continued efficacy. Importantly, he also reported a significant reduction in social anxiety related to his cataplexy, which has allowed him to pursue fulfilling relationships and career opportunities that were previously impossible.

Patient 2

A 54-year-old man initially reported excessive daytime sleepiness in his early 20s; around the age of 30, this sleepiness was followed by facial cataplexy. The patient also exhibited occasional dream-enactment behavior compatible with REM sleep behavior disorder (rarely, these had resulted in minor punches of his wife). At the age of 37, the patient sought care and was diagnosed with narcolepsy type 1 after undergoing polysomnography and multiple sleep latency tests. He was treated with partial success with modafinil 500 mg daily in two doses and paroxetine 40 mg. Past trials of methylphenidate and sodium oxybate were not tolerated. The patient was referred to our center at the age of 52 years for progressive worsening in severity of cataplexy over the previous year. At that time, he reported partial cataplexy up to 50 times daily, which was characterized by jaw weakness and dysarthria with head dropping. Full cataplexy, often resulting in complete falls, occurred several times per week and lasted up to 2 minutes. Some of these episodes occurred in dangerous situations, including while swimming and while climbing a ladder. Typical triggers were laughter, anger, and surprise; however, the episodes had begun to occur spontaneously, particularly if he was feeling fatigued. The patient reported that his cataplexy was by far the most invalidating symptom of his narcolepsy, with significant impairment in social and occupational functioning, resulting in invalidity from his previous employment as a factory worker. At this time, the patient was also diagnosed with severe obstructive sleep apnea (apnea-hypopnea index: 54/h), which was successfully treated with continuous airway pressure therapy. For his cataplexy, the patient was treated with clomipramine titrated up to 75 mg daily, replacing paroxetine. After several months of further worsening of cataplexy, paroxetine was reintroduced concomitantly with clomipramine. No improvement was noted over the following year. The patient reported frequent complete cataplexy episodes occurring multiple times daily upon minor emotional triggers. At this point, tropatepine was introduced at 10 mg. The patient reported rapid improvement in his cataplexy. At the most recent follow-up, 10 months after the introduction of tropatepine, he reported only occasional attacks of facial cataplexy, occurring up to three times per week. The patient's wife also reported a decrease in frequency of dream enactment behavior, with only occasional somniloquy and no violent behaviors remaining. The patient did not report any modification in his daytime somnolence, which remained significant but was well managed with a programmed nap schedule. The treatment is well tolerated, with the patient noting only mild mouth dryness.

Patient 3

A 78-year-old woman had been diagnosed with late-onset narcolepsy at age 53. She had a typical history of excessive

daytime somnolence with irrepressible sleep attacks followed by onset of facial cataplexy triggered by laughing. She was otherwise known to have degenerative disk disease, osteoarthritis of the hip requiring hip replacement, hypertension, and hypothyroidism. She lived alone and remained fully independent in activities of daily living, with no significant cognitive impairment. After having been satisfactorily treated with a combination of modafinil and escitalopram for several years, the patient was referred to our tertiary sleep unit at the age of 74 for worsening cataplexy. In recent years, she had begun experiencing complete cataplectic attacks more frequently. She reported that when playing tag with her young granddaughter, she would run around the table laughing with her granddaughter in pursuit, only to be caught lying on the ground as her cataplexy overwhelmed her. These attacks, precipitated by strong laughter, occurred several times per month and had resulted, on at least one occasion, in a minor occipital trauma, and the patient and her family were increasingly concerned with her risk of injury. She also reported frequent, bothersome nightmares, often culminating in hypnopompic hallucinations. Escitalopram was discontinued, and the patient was successively treated over the next 4 years with clomipramine, followed by combined paroxetine and pitolisant, the latter of which replaced her modafinil. None of these treatments proved more than modestly effective for her cataplexy, although 18 mg of pitolisant resulted in a significant improvement in her daytime sleepiness. Despite adherent use of pitolisant and paroxetine, the patient's cataplexy continued to worsen, and she reported multiple daily episodes of both partial and complete cataplexy. She also reported that the emotional threshold necessary to trigger cataplexy had become progressively lower, such that even mild bemusement could trigger attacks. Considering the significant risk for injury in this older patient, tropatepine was introduced at a dose of 5 mg. At last follow-up, 2 months after initiation of the treatment, the patient reported complete resolution of both complete and partial cataplexy within 1 week of treatment initiation. She also reported complete resolution of both nightmares and hypnopompic hallucinations. The patient, who continues to live independently, reported no significant cognitive side effects but did complain of mild dryness of her mouth.

DISCUSSION

To our knowledge, this is the first report of successful treatment of cataplexy using a specific anticholinergic drug. Although this class of drug has not commonly been used in the treatment of cataplexy, its use is rational when one considers the important role acetylcholine plays in the genesis of both REM sleep and muscle atonia.

The critical role of acetylcholine in REM sleep has been demonstrated in animal models dating back to the era of REM sleep discovery. Jouvet and colleagues demonstrated in seminal works in cats that the infusion of carbachol (a potent cholinergic, muscarinic agonist) in the mediodorsal pontine tegmentum produces both the clinical and electrophysiological features of REM sleep, a finding later replicated in several feline and murine models.^{5,6} Moreover, administration of anticholinergic agents have been shown, although less consistently, to reverse these physiological features.⁶ Recently, a loss of function model

in knockout mice demonstrated that specific muscarinic receptors, *Chrm1* and *Chrm3*, are necessary to generate REM sleep and provides further evidence supporting the essential role of acetylcholine in REM sleep.⁷

Cataplexy is thought to represent the intrusion of REM sleep atonia into wakefulness, resulting from the abnormal activation of the subcoeruleus nucleus (an equivalent of the perlocus coeruleus alpha in the cat and of the sublateralodorsalis nucleus in the rat) by overactive limbic structures.^{1,8} Data from canine studies suggest that this process is mediated in part by increased cholinergic tone. Mignot and colleagues have shown that injection of carbachol into the pontine reticular formation precipitates cataplexy in a dose-dependent fashion in narcoleptic dogs.⁹ A similar response can be observed in non-narcoleptic dogs, although significantly higher doses are required. Taken together, these findings suggest that cholinergic hypersensitivity in the pontine reticular formation, via its reciprocal connections to limbic structures, facilitates the pathological recruitment of REM atonia-generating circuits in response to salient emotional stimuli.

Considering the abundant evidence demonstrating the importance of acetylcholine in cataplexy and REM sleep, it is logical to attempt treatment of cataplexy with specific anticholinergic agents. Indeed, the dramatic and prompt therapeutic response to the muscarinic antagonist tropatepine in our report of three patients with severe and drug-resistant cataplexy lends credence to this approach. Additionally, although tricyclic antidepressants are thought to exert their efficacy in the treatment of cataplexy primarily through their monoaminergic properties, it is reasonable to hypothesize their substantial anticholinergic activity is a contributing factor. Interestingly, two of our patients exhibited other signs of REM sleep dysfunction, including REM sleep behavior disorder and nightmares with hypnagogic hallucinations, respectively. The observed improvement in these symptoms with tropatepine may be related to the REM sleep-suppressing properties of anticholinergics. Tropatepine has a long half-life (40 hours), which may be an advantage compared with venlafaxine's short half-life, which can result in rebound cataplexy when a single dose is forgotten.¹⁰ Tropatepine is a common drug, marketed since 1975, that may induce atropinic side effects (urine retention, constipation, blurred vision, rare confusion). The benefit-to-risk ratio was excellent in our patients, as side effects were limited to nondisturbing dry mouth. Although the specific drug tropatepine may not be widely available outside of France, we posit that it is reasonable to consider trials of other, more widely available, antimuscarinic agents commonly used in neurology, such as benztropine or trihexyphenidyl, in resistant cataplexy.

CONCLUSIONS

In this report of three narcoleptic patients, tropatepine was a potent treatment for severe, disabling, and drug-resistant cataplexy and may represent an efficacious and cost-effective treatment for drug-resistant cataplexy, as well as other features of REM sleep dysfunction commonly observed in narcolepsy. The success of this treatment approach also reemphasizes the role of cholinergic mechanisms in the genesis of cataplexy and may constitute a rationale for trials of other anticholinergic agents,

such as benztropine or trihexyphenidyl, in countries where tropatepine is unavailable.

ABBREVIATION

REM, rapid eye movement

REFERENCES

1. Bassetti CLA, Adamantidis A, Burdakov D, et al. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. *Nat Rev Neurol*. 2019;15(9):519–539.
2. Morgenthaler TI, Kapur VK, Brown T, et al. Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. *Sleep*. 2007;30(12):1705–1711.
3. Lambert A, dachary JM, Marie C, et al. [A new synthetic antiparkinsonian drug, tropatepine hydrochloride in extrapyramidal syndromes induced by neuroleptics]. *Encephale*. 1976;2(2):115–121.
4. Lecendreau M, Maret S, Bassetti C, Mouren MC, Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. *J Sleep Res*. 2003;12(4):347–348.
5. Vanni-Mercier G, Sakai K, Lin JS, Jouvet M. Carbachol microinjections in the mediodorsal pontine tegmentum are unable to induce paradoxical sleep after caudal pontine and prebulbar transections in the cat. *Neurosci Lett*. 1991;130(1):41–45.
6. Grace KP, Horner RL. Evaluating the evidence surrounding pontine cholinergic involvement in REM sleep generation. *Front Neurol*. 2015;6(190):190.
7. Niwa Y, Kanda GN, Yamada RG, et al. Muscarinic acetylcholine receptors *Chrm1* and *Chrm3* are essential for REM sleep. *Cell Rep*. 2018;24(9):2231–2247.e7.
8. Horner RL, Peever JH. Brain circuitry controlling sleep and wakefulness. *Continuum (Minneapolis)*. 2017;23(4, Sleep Neurology):955–972.
9. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. *Prog Neurobiol*. 1997;52(1):27–78.
10. Bun H, Monjanel-Mouterde S, Audebert C, Vincent Du Laurier M, Durand A, Cano JP. Pharmacokinetics of tropatepine in healthy volunteers. *Clin Drug Investig*. 1997;14(1):53–60.

ACKNOWLEDGMENTS

The authors warmly thank Fabien Genty for his contribution to this article.

SUBMISSION & CORRESPONDENCE INFORMATION

Submitted for publication October 31, 2020

Submitted in final revised form November 18, 2020

Accepted for publication November 18, 2020

Address correspondence to: Prof. Isabelle Arnulf, MD, PhD, Service des Pathologies du Sommeil, Hôpital Pitié-Salpêtrière, 47-83 Bd de l'Hôpital, 75013 Paris, France; Tel: 33 (0) 1 42 16 77 02/04; Fax: 33 (0) 1 42 16 77 00; Email: isabelle.arnulf@aphp.fr

DISCLOSURE STATEMENT

Work was performed at the Sleep Disorders Unit, Pitié-Salpêtrière University Hospital, Paris, France. No specific financial support was allocated to this project. All authors have seen and approved the manuscript. M.N. has received an educational grant from Paladin Labs Pharmaceuticals. S.L.S. has speaking engagements with UCB Pharma. I.A. has received consultant fees from Idorsia Pharma, Ono Pharma, and UCB Pharma. None of the financial disclosures is relevant to the submitted work. This report describes off-label use of the medication tropatepine.